Emerging Adjuvant Thrombolytic Therapies for Acute Ischemic Stroke Reperfusion.

reperfusion stroke thrombectomy thrombolytic therapy treatment outcome

Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
06 Aug 2024
Historique:
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: aheadofprint

Résumé

Thrombolytic therapies for acute ischemic stroke are widely available but only result in recanalization early enough, to be therapeutically useful, in 10% to 30% of cases. This large gap in treatment effectiveness could be filled by novel therapies that can increase the effectiveness of thrombus clearance without significantly increasing the risk of harm. This focused update will describe the current state of emerging adjuvant treatments for acute ischemic stroke reperfusion. We focus on new treatments that are designed to (1) target different components that make up a stroke thrombus, (2) enhance endogenous fibrinolytic systems, (3) reduce stagnant blood flow, and (4) improve recanalization of distal thrombi and postendovascular thrombectomy.

Identifiants

pubmed: 39105286
doi: 10.1161/STROKEAHA.124.045755
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Vignan Yogendrakumar (V)

Division of Neurology, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Canada (V.Y.).
Department of Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Australia (V.Y., B.C.V.C.).

Sarah Vandelanotte (S)

Laboratory for Thrombosis Research, KU Leuven Campus Kulak, Kortrijk, Belgium (S.V., S.F.D.M.).

Eva A Mistry (EA)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (E.A.M., J.P.B.).

Michael D Hill (MD)

Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Canada (M.D.H., S.B.C.).

Shelagh B Coutts (SB)

Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Canada (M.D.H., S.B.C.).

Raul G Nogueira (RG)

Department of Neurology, University of Pittsburgh, PA (R.G.N.).

Thanh N Nguyen (TN)

Department of Neurology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA (T.N.N.).

Robert L Medcalf (RL)

Central Clinical School, Australian Centre for Blood Diseases, Monash University, Australia (R.L.M.).

Joseph P Broderick (JP)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (E.A.M., J.P.B.).
Gardner Neuroscience Institute, Cincinnati, OH (J.P.B.).

Simon F De Meyer (SF)

Laboratory for Thrombosis Research, KU Leuven Campus Kulak, Kortrijk, Belgium (S.V., S.F.D.M.).

Bruce C V Campbell (BCV)

Department of Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Australia (V.Y., B.C.V.C.).

Classifications MeSH